| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= DBP 95‐115 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
Cilazapril 2.5 mg: n=54(36 males,18 females); mean age=55.6(10.1) years; baseline sitting SBP=162.5(15.1) mm Hg, DBP=102.4(5.4) mm Hg;
Cilazapril 5 mg: n=55(32 males,23 females); mean age=55.6(10.8) years; baseline sitting SBP=158.8(16.5) mm Hg, DBP=100.8(4.3) mm Hg;
Placebo: n=53(29 males,24 females); mean age=58.1(9.5) years; baseline sitting SBP=161.4(16.5) mm Hg, DBP=102.1(5.7) mm Hg |
| Interventions |
Cilazapril 2.5 mg once daily;
Cilazapril 5 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Table 2, p. S95; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
